Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025听Financial Results
Xilio Therapeutics (NASDAQ:XLO) reported Q2 2025 financial results and pipeline updates. The company's lead candidate vilastobart showed promising Phase 2 data with a 26% objective response rate in metastatic MSS colorectal cancer patients without liver metastases. The therapy demonstrated deep, durable responses and a differentiated safety profile.
Financial highlights include $121.6 million in cash and cash equivalents, a net loss of $15.8 million, and revenue of $8.1 million. The company completed a follow-on offering raising $50.0 million in initial gross proceeds, with potential for additional $100.0 million from warrant exercises.
Xilio expects to nominate development candidates for its masked T cell engager programs in H2 2025 and projects cash runway through Q3 2026.
Xilio Therapeutics (NASDAQ:XLO) ha reso noti i risultati finanziari del secondo trimestre 2025 e aggiornamenti sul portafoglio. Il candidato principale, vilastobart, ha riportato dati di fase 2 promettenti con un tasso di risposta obiettiva del 26% nei pazienti con carcinoma colorettale metastatico MSS privi di metastasi epatiche. La terapia ha mostrato risposte profonde e durature e un profilo di sicurezza distintivo.
I punti finanziari includono $121.6 million in contanti e equivalenti, una perdita netta di $15.8 million e ricavi per $8.1 million. L'azienda ha completato un'offerta successiva raccogliendo $50.0 million di proventi lordi iniziali, con la possibilit脿 di ulteriori $100.0 million derivanti dall'esercizio di warrant.
Xilio prevede di selezionare i candidati allo sviluppo per i suoi programmi di T cell engager mascherati nella seconda met脿 del 2025 e stima di avere liquidit脿 sufficiente fino al terzo trimestre 2026.
Xilio Therapeutics (NASDAQ:XLO) anunci贸 los resultados financieros del segundo trimestre de 2025 y actualizaciones de su cartera. Su candidato principal, vilastobart, present贸 datos de fase 2 prometedores con una tasa de respuesta objetiva del 26% en pacientes con c谩ncer colorrectal metast谩sico MSS sin met谩stasis hep谩ticas. El tratamiento mostr贸 respuestas profundas y duraderas y un perfil de seguridad diferenciado.
En lo financiero, la compa帽铆a dispone de $121.6 million en efectivo y equivalentes, registr贸 una p茅rdida neta de $15.8 million y obtuvo ingresos por $8.1 million. Complet贸 una oferta posterior a la IPO recaudando $50.0 million de ingresos brutos iniciales, con la posibilidad de otros $100.0 million por el ejercicio de warrants.
Xilio espera nominar candidatos a desarrollo para sus programas de T cell engagers enmascarados en la segunda mitad de 2025 y proyecta liquidez suficiente hasta el tercer trimestre de 2026.
Xilio Therapeutics (NASDAQ:XLO)電� 2025雲� 2攵勱赴 鞛 鞁れ爜瓿� 韺岇澊頂勲澕鞚� 鞐呺嵃鞚错姼毳� 氚滍憸頄堨姷雼堧嫟. 欤茧牓 頉勲炒氍检 vilastobart電� 臧� 鞝勳澊臧� 鞐嗠姅 鞝勳澊靹� MSS 雽�鞛レ晹 頇橃瀽鞐愳劀 臧濌磤鞝� 氚橃潙毳� 26%毳� 氤挫澊電� 鞙犽頃� 2靸� 雿办澊韯半ゼ 雮橅儉雰堨姷雼堧嫟. 鞚� 旃橂氩曥潃 臧曧晿瓿� 歆�靻嶌爜鞚� 氚橃潙瓿� 彀硠頇旊悳 鞎堨爠靹� 頂勲韺岇澕鞚� 氤挫棳欤检棃鞀惦媹雼�.
鞛 頃橃澊霛检澊韸鸽電� $121.6 million鞚� 順勱笀 氚� 順勱笀靹� 鞛愳偘, $15.8 million鞚� 靾滌啇鞁�, 攴鸽Μ瓿� $8.1 million鞚� 毵れ稖鞚� 韽暔霅╇媹雼�. 須岇偓電� 頉勳啀 瓿惦毳� 韱淀暣 齑堦赴 齑� 靾橃澋 $50.0 million鞚� 頇曤炒頄堨溂氅�, 鞗岆煱韸� 頄夓偓搿� 於旉皜 $100.0 million 頇曤炒 臧�電レ劚鞚� 鞛堨姷雼堧嫟.
Xilio電� 2025雲� 頃橂皹旮办棎 毵堨姢韨闺悳 T靹疙彫 鞐旉矊鞚挫爛 頂勲攴鸽灗鞚� 臧滊皽 頉勲炒毳� 歆�氇呿暊 瓿勴殟鞚措┌, 2026雲� 3攵勱赴旯岇 順勱笀鞙茧 鞖挫榿鞚� 臧�電ロ暊 瓴冹溂搿� 鞝勲頃╇媹雼�.
Xilio Therapeutics (NASDAQ:XLO) a communiqu茅 ses r茅sultats financiers du deuxi猫me trimestre 2025 et des mises 脿 jour de son portefeuille. Le candidat principal, vilastobart, a affich茅 des donn茅es de phase 2 prometteuses avec un taux de r茅ponse objective de 26% chez des patients atteints d'un cancer colorectal m茅tastatique MSS sans m茅tastases h茅patiques. Le traitement a d茅montr茅 des r茅ponses profondes et durables ainsi qu'un profil de s茅curit茅 diff茅renci茅.
Parmi les points financiers : $121.6 million de tr茅sorerie et 茅quivalents, une perte nette de $15.8 million et des revenus de $8.1 million. La soci茅t茅 a r茅alis茅 une op茅ration d'augmentation de capital secondaire g茅n茅rant $50.0 million de produit brut initial, avec la possibilit茅 d'obtenir $100.0 million suppl茅mentaires via l'exercice de warrants.
Xilio pr茅voit de nommer des candidats au d茅veloppement pour ses programmes de T鈥慶ell engagers masqu茅s au second semestre 2025 et estime disposer de liquidit茅s jusqu'au 3e trimestre 2026.
Xilio Therapeutics (NASDAQ:XLO) legte die Finanzergebnisse f眉r das zweite Quartal 2025 sowie Updates zum Portfolio vor. Der f眉hrende Wirkstoffkandidat vilastobart zeigte vielversprechende Phase鈥�2鈥慏aten mit einer objektiven Ansprechrate von 26% bei Patient:innen mit metastasiertem MSS鈥慏armkrebs ohne Lebermetastasen. Die Therapie erzielte tiefe, anhaltende Ansprechraten und ein differenziertes Sicherheitsprofil.
Zu den finanziellen Eckdaten geh枚ren $121.6 million an Zahlungsmitteln und Zahlungsmittel盲quivalenten, ein Nettoverlust von $15.8 million sowie Umsatzerl枚se in H枚he von $8.1 million. Das Unternehmen schloss eine Follow鈥憃n鈥慞latzierung ab und erzielte anf盲nglich $50.0 million Bruttoerl枚s, mit der Option auf weitere $100.0 million durch die Aus眉bung von Warrants.
Xilio erwartet, in H2 2025 Entwicklungskandidaten f眉r seine maskierten T鈥慫ell鈥慐ngager鈥慞rogramme zu nominieren und projiziert eine Finanzierung bis zum 3. Quartal 2026.
- Promising Phase 2 data showing 26% objective response rate for vilastobart in MSS colorectal cancer
- Strong cash position of $121.6 million, with runway through Q3 2026
- Successful $50M follow-on offering with potential additional $100M from warrants
- Revenue increased to $8.1M from $2.4M year-over-year
- Strategic partnerships with Gilead and AbbVie advancing pipeline development
- Net loss increased to $15.8M from $13.9M year-over-year
- R&D expenses increased to $15.3M from $11.2M year-over-year
- G&A expenses rose to $7.1M from $5.8M year-over-year
- Discontinued investment in XTX202 tumor-activated IL-2 program
Insights
Xilio reports promising tumor-activated immunotherapy data while securing runway through Q3 2026 with $121.6M cash position.
Xilio Therapeutics' Q2 results reveal significant progress across their innovative tumor-activated immunotherapy pipeline. The standout program is vilastobart, their masked anti-CTLA-4 antibody, which demonstrated a
Their proprietary masking technology appears to be gaining clinical validation across multiple platforms. Beyond vilastobart, their IL-12 program (XTX301) has completed Phase 1A dose escalation with Gilead as partner, while their masked PD-1/IL-2 bispecific (XTX501) is advancing toward IND submission by mid-2026. Most promising is their emerging portfolio of masked T cell engagers targeting PSMA, CLDN18.2, and STEAP1, with development candidates expected in Q3-Q4 2025.
Financially, Xilio has significantly strengthened its position with
Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy
On track with plans to nominate first development candidates for wholly owned masked T cell engager programs in second half of 2025
WALTHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics,听Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the second quarter ended June 30, 2025.
鈥淒uring the second quarter, we continued to make strong progress across our pipeline of novel tumor-activated immuno-oncology therapies, and with our recent financing, we believe that we are well-positioned to execute on our strategic goals,鈥� said Ren茅 Russo, Pharm.D., president and chief executive officer of Xilio. 鈥淲e believe our masked T cell engager molecules have the potential to be best-in-class, and we anticipate nominating our first development candidates for our wholly owned programs later this year. In addition, we are very encouraged by the clinical progress for XTX301, our tumor-activated IL-12 advancing in partnership with Gilead, and we look forward to providing a program update in the near-term. We also recently reported updated Phase 2 combination data for vilastobart at ASCO and believe these data not only highlight the significant opportunity for vilastobart across a range of I-O combinations and tumor types, but also provide further clinical validation for our proprietary masking technology and approach.鈥�
Pipeline and Business Updates
Vilastobart: tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4
Vilastobart is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells when activated in the tumor microenvironment (TME). Vilastobart is currently being evaluated in combination with atezolizumab (Tecentriq庐) in Phase 1C combination dose escalation in patients with advanced solid tumors and in a Phase 2 clinical trial in patients with metastatic microsatellite stable (MSS) colorectal cancer (CRC).
- In May 2025, Xilio announced promising updated Phase 2 data for vilastobart in combination with atezolizumab in patients with metastatic MSS CRC at the American Society of Clinical Oncology (ASCO) Annual Meeting. These data demonstrated a preliminary
26% objective response rate in heavily pre-treated metastatic MSS CRC patients without liver metastases, including deep and durable responses accompanied by substantial decreases in tumor biomarkers and improvements in clinical symptoms, as well as a differentiated and well-tolerated safety profile with a low incidence of colitis and other immune-related adverse events, which have historically limited the potential for anti-CTLA-4 therapies. For more information, read the press release . Xilio anticipates reporting additional data from the Phase 2 trial in the first half of 2026. - Based on the encouraging clinical data to date, Xilio believes vilastobart has the potential to be an I-O combination agent of choice and be combined with a range of existing and next-generation agents. Xilio continues to engage strategic partners on potential opportunities to accelerate and expand further development for vilastobart.
XTX301: tumor-activated IL-12
XTX301 is an investigational tumor-activated IL-12 designed to potently stimulate anti-tumor immunity and reprogram the TME of poorly immunogenic 鈥渃old鈥� tumors towards an inflamed or 鈥渉ot鈥� state. In March 2024, Xilio entered into an exclusive license agreement with Gilead Sciences, Inc. (Gilead) related to Xilio鈥檚 tumor-activated IL-12 program, including XTX301. Xilio is evaluating XTX301 as a monotherapy in an ongoing Phase 1 clinical trial in patients with advanced solid tumors.
- Xilio recently completed enrollment in Phase 1A monotherapy dose escalation and evaluation of those patients is ongoing. In addition, Xilio continues to enroll patients in Phase 1B monotherapy dose expansion of the ongoing Phase 1 clinical trial of XTX301.
XTX501: masked PD-1/IL-2 bispecific
XTX501 is a novel, tumor-activated bispecific PD-1/IL-2 designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function. XTX501 incorporates masking designed to overcome IL-2 receptor-mediated clearance and peripheral activity. In preclinical studies, XTX501 demonstrated robust monotherapy activity (including in settings insensitive to PD-1) and tumor-selective pharmacodynamics consistent with its intended mechanism of action.
- Xilio is continuing to advance XTX501 in investigational new drug (IND)-enabling studies and plans to submit an IND application for XTX501 in the middle of 2026.
Masked T Cell Engager Programs
Xilio is leveraging its proprietary, clinically validated tumor-activation platform to advance multiple preclinical programs for masked T cell engagers, including wholly owned programs targeting the tumor-associated antigens for PSMA, CLDN18.2 and STEAP1 and an additional program in collaboration with AbbVie.
Xilio鈥檚 masked T cell engager programs include bispecific molecules designed using its advanced tumor-activated cell engager (ATACR) format, which consists of a T cell engager with a masked CD3 targeting domain, and tri-specific molecules designed using its selective effector-enhanced cell engager (SEECR) format. The SEECR format builds upon the ATACR format by adding co-stimulatory signaling designed to further enhance potency and T cell activation.
- Xilio anticipates nominating development candidates for its PSMA program (ATACR format), CLDN18.2 program (ATACR format) and STEAP1 program (SEECR format) in the third quarter of 2025, fourth quarter of 2025 and first half of 2026, respectively.
- Xilio anticipates advancing at least two of these programs into initial IND-enabling studies and submitting IND applications for those programs in 2027.
Corporate Updates
- In June 2025, Xilio closed a follow-on public offering of prefunded warrants and accompanying common stock warrants and received initial gross proceeds of approximately
$50.0 million before deducting underwriting discounts and commissions and offering expenses. In connection with the offering, Xilio issued Series B and Series C common stock warrants and will receive up to$100.0 million of additional gross proceeds by the second half of 2026 if all of those warrants are exercised in cash at their initial exercise price of$0.75 per warrant. The financing was co-led by new investors Coastlands Capital and Frazier Life Sciences and included participation from Gilead Sciences, Inc., Logos Capital, Samsara BioCapital and other new and existing institutional investors. For more information, read the press release . - In June 2025, Xilio announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company鈥檚 board of directors. For more information, read the press release .
Second Quarter 2025 Financial Results
- Cash Position:听Cash and cash equivalents were
$121.6 million as of June 30, 2025, compared to$55.3 million as of December 31, 2024. In the second quarter of 2025, Xilio received$47.0 million in net proceeds from its June 2025 follow-on public offering after deducting underwriting discounts and commissions and offering expenses payable by the company. - Collaboration and License Revenue: Collaboration and license revenue was
$8.1 million for the quarter ended June 30, 2025, compared to$2.4 million for the quarter ended June 30, 2024. Collaboration and license revenue for the quarter ended June 30, 2025 consisted of revenue recognized in connection with Xilio鈥檚 collaborations with AbbVie and Gilead, and collaboration and license revenue for the quarter ended June 30, 2024 consisted of revenue recognized in connection with Xilio鈥檚 collaboration with Gilead. - Research听& Development (R&D) Expenses:听R&D expenses were
$15.3 million for the quarter ended June 30, 2025, compared to$11.2 million for the quarter ended June 30, 2024. The increase was primarily driven by increased clinical development activities related to vilastobart, increased costs related to early-stage programs and indirect research and development and increased personnel-related costs, which were partially offset by decreased costs related to clinical development activities for XTX202, a tumor-activated IL-2, as a result of discontinuing further investment in that program. For the quarter ended June 30, 2025, R&D expenses also included manufacturing activities related to IND-enabling studies and preclinical development activities for XTX501, which were not separately tracked for the quarter ended June 30, 2024 as the company had not yet begun performing IND-enabling studies. For the quarter ended June 30, 2024, R&D expenses also included a$1.0 million development milestone under the CTLA-4 monoclonal antibody license agreement with WuXi Biologics (Hong Kong) Limited for which there was no comparable cost for the quarter ended June 30, 2025. - General听& Administrative (G&A) Expenses:听G&A expenses were
$7.1 million for the quarter ended June 30, 2025, compared to$5.8 million for the quarter ended June 30, 2024. The increase was primarily driven by an increase in professional and consulting fees, including legal fees and other professional costs, and an increase in personnel-related costs, which were partially offset by a decrease in costs related to directors鈥� and officers鈥� liability insurance. - Net Loss:听Net loss was
$15.8 million for the quarter ended June 30, 2025, compared to$13.9 million for the quarter ended June 30, 2024.
Financial Guidance
Based on its current operating plans, Xilio anticipates that its cash and cash equivalents as of June 30, 2025 will be sufficient to enable it to fund its operating expenses and capital expenditure requirements through the end of the third quarter of 2026.
About Vilastobart
Vilastobart is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells when activated in the tumor microenvironment (TME). In 2023, Xilio entered into a co-funded clinical trial collaboration with Roche to evaluate vilastobart in combination with atezolizumab (Tecentriq庐) in a multi-center, open-label Phase 1/2 clinical trial. Xilio is currently evaluating the safety and tolerability of the combination in Phase 1C dose escalation in patients with advanced solid tumors and the safety and efficacy of the combination in Phase 2 in patients with metastatic microsatellite stable colorectal cancer with and without liver metastases. Please refer to NCT04896697 on听听for additional details.
About XTX301
XTX301 is an investigational tumor-activated IL-12 designed to potently stimulate anti-tumor immunity and reprogram the tumor microenvironment (TME) of poorly immunogenic 鈥渃old鈥� tumors towards an inflamed or 鈥渉ot鈥� state. In March 2024, Xilio entered into an exclusive license agreement with Gilead Sciences, Inc. for Xilio鈥檚 tumor-activated IL-12 program, including XTX301. Xilio is evaluating the safety and tolerability of XTX301 as a monotherapy in patients with advanced solid tumors in the Phase 1 portion of a first-in-human, multi-center, open-label Phase 1/2 clinical trial. Please refer to NCT05684965 on听听for additional details.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting听听and follow us on LinkedIn (.).
Cautionary Note听Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, expectations, development timelines and anticipated milestones for Xilio鈥檚 programs; the timing of data releases or program updates; the timing and potential receipt of cash proceeds upon the exercise of common stock warrants issued in connection with the June 2025 follow-on public offering; the receipt of future contingent payments under Xilio鈥檚 collaboration or partnership agreements with AbbVie or Gilead; the ability to partner vilastobart and expand and accelerate further development; the potential benefits of any of Xilio鈥檚 current or future product candidates in any indication; the sufficiency of, and the period in which Xilio expects to have, cash to fund its operations, capital expenditure requirements, and development plans and milestones; and Xilio鈥檚 strategy, goals and anticipated financial performance, milestones, business plans and focus. The words 鈥渁im,鈥� 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渃ould,鈥� 鈥渨ould,鈥� 鈥渟hould,鈥� 鈥渆xpect,鈥� 鈥減lan,鈥� 鈥渁nticipate,鈥� 鈥渋ntend,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥減otential,鈥� 鈥渃ontinue,鈥� 鈥渟eek,鈥� 鈥渢arget鈥� and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management鈥檚 current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks related to general market conditions and geopolitical uncertainties; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio鈥檚 current or future product candidates; Xilio鈥檚 ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates; Xilio鈥檚 ability to advance multiple early stage masked T cell engager programs; initial, preliminary or interim preclinical or clinical data or results may not be replicated in or predictive of future preclinical or clinical data or results; Xilio鈥檚 ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; results from preclinical studies or clinical trials for Xilio鈥檚 product candidates may not support further development of such product candidates; actions of regulatory agencies may affect the initiation, timing and progress of current or future clinical trials; Xilio鈥檚 ability to obtain, maintain and enforce patent and other intellectual property protection for current or future product candidates; Xilio鈥檚 need to obtain additional cash resources to advance its pipeline of tumor-activated I-O molecules; the impact of international trade policies on Xilio鈥檚 business, including U.S. and China trade policies; and Xilio鈥檚 ability to maintain its collaboration or partnership agreements with AbbVie, Gilead and Roche. These and other risks and uncertainties are described in greater detail in the sections entitled 鈥淩isk Factor Summary鈥� and 鈥淩isk Factors鈥� in Xilio鈥檚 filings with the U.S. Securities and Exchange Commission (鈥淪EC鈥�), including Xilio鈥檚 most recent Quarterly Report on Form 10-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio鈥檚 views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
TECENTRIQ is a registered trademark of Genentech USA, Inc., a member of the Roche Group.
Investor Contact
Media Contact
Dan Budwick
1AB
| XILIO THERAPEUTICS,听INC. Condensed Consolidated Balance Sheets (In thousands) (Unaudited) | ||||||||
| 听 | ||||||||
| 听 | 听 | June 30, 2025 | 听 | December 31, 2024 | ||||
| Assets | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Cash and cash equivalents | 听 | $ | 121,551 | 听 | 听 | $ | 55,291 | 听 |
| Other assets | 听 | 听 | 12,262 | 听 | 听 | 听 | 15,784 | 听 |
| Total assets | 听 | $ | 133,813 | 听 | 听 | $ | 71,075 | 听 |
| Liabilities and Stockholders鈥� Equity | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Liabilities | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Deferred revenue | 听 | $ | 70,910 | 听 | 听 | $ | 32,780 | 听 |
| Common stock warrant liabilities | 听 | 听 | 38,550 | 听 | 听 | 听 | 鈥� | 听 |
| Other liabilities | 听 | 听 | 17,284 | 听 | 听 | 听 | 20,697 | 听 |
| 听 听 Total liabilities | 听 | $ | 126,744 | 听 | 听 | $ | 53,477 | 听 |
| Stockholders鈥� equity | 听 | 听 | 7,069 | 听 | 听 | 听 | 17,598 | 听 |
| Total liabilities and stockholders鈥� equity | 听 | $ | 133,813 | 听 | 听 | $ | 71,075 | 听 |
| XILIO THERAPEUTICS,听INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share data) (Unaudited) | ||||||||||||||||
| 听 | ||||||||||||||||
| 听 | 听 | Three Months Ended June听30,听 | 听 | Six Months Ended June听30,听 | ||||||||||||
| 听 | 听 | 2025 | 听 | 听 | 2024 | 听 | 听 | 2025 | 听 | 听 | 2024 | 听 | ||||
| Collaboration and license revenue | 听 | $ | 8,084 | 听 | 听 | $ | 2,357 | 听 | 听 | $ | 11,014 | 听 | 听 | $ | 2,357 | 听 |
| Operating expenses (1) | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Research and development | 听 | $ | 15,330 | 听 | 听 | $ | 11,216 | 听 | 听 | $ | 23,596 | 听 | 听 | $ | 21,616 | 听 |
| General and administrative | 听 | 听 | 7,120 | 听 | 听 | 听 | 5,815 | 听 | 听 | 听 | 15,635 | 听 | 听 | 听 | 11,954 | 听 |
| Restructuring | 听 | 听 | 鈥� | 听 | 听 | 听 | 30 | 听 | 听 | 听 | 鈥� | 听 | 听 | 听 | 978 | 听 |
| Total operating expenses | 听 | 听 | 22,450 | 听 | 听 | 听 | 17,061 | 听 | 听 | 听 | 39,231 | 听 | 听 | 听 | 34,548 | 听 |
| Loss from operations | 听 | 听 | (14,366 | ) | 听 | 听 | (14,704 | ) | 听 | 听 | (28,217 | ) | 听 | 听 | (32,191 | ) |
| Other income (expense), net | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Change in fair value of common stock warrant liabilities | 听 | 听 | (50 | ) | 听 | 听 | 鈥� | 听 | 听 | 听 | (50 | ) | 听 | 听 | 鈥� | 听 |
| Other income (expense), net | 听 | 听 | (1,428 | ) | 听 | 听 | 779 | 听 | 听 | 听 | (842 | ) | 听 | 听 | 1,063 | 听 |
| Total other income (expense), net | 听 | 听 | (1,478 | ) | 听 | 听 | 779 | 听 | 听 | 听 | (892 | ) | 听 | 听 | 1,063 | 听 |
| Net loss and comprehensive loss | 听 | $ | (15,844 | ) | 听 | $ | (13,925 | ) | 听 | $ | (29,109 | ) | 听 | $ | (31,128 | ) |
| Net loss per share, basic and diluted | 听 | $ | (0.16 | ) | 听 | 听 | (0.24 | ) | 听 | $ | (0.34 | ) | 听 | $ | (0.73 | ) |
| Weighted average common shares outstanding, basic and diluted (2) | 听 | 听 | 96,447,672 | 听 | 听 | 听 | 57,760,178 | 听 | 听 | 听 | 85,634,094 | 听 | 听 | 听 | 42,836,381 | 听 |
| (1) | Operating expenses include the following amounts of non-cash stock-based compensation expense: |
| 听 | 听 | Three Months Ended June 30, | 听 | Six Months Ended June 30, | ||||||||||||
| 听 | 听 | 2025 | 听 | 2024 | 听 | 2025 | 听 | 听 | 2024 | 听 | ||||||
| Research and development expense | 听 | $ | 346 | 听 | 听 | $ | 385 | 听 | 听 | $ | 735 | 听 | 听 | $ | 891 | 听 |
| General and administrative expense | 听 | 听 | 1,005 | 听 | 听 | 听 | 1,126 | 听 | 听 | 听 | 2,151 | 听 | 听 | 听 | 2,453 | 听 |
| Total stock-based compensation expense | 听 | $ | 1,351 | 听 | 听 | $ | 1,511 | 听 | 听 | $ | 2,886 | 听 | 听 | $ | 3,344 | 听 |
| (2) | Weighted average common shares outstanding, basic and diluted, includes prefunded warrants to purchase common stock issued in connection with (i) the company鈥檚 private placements with certain existing investors and Gilead and (ii) the company鈥檚 June 2025 follow-on public offering, as the prefunded warrants are exercisable at any time for nominal cash consideration. |
FAQ
What were Xilio Therapeutics' (XLO) key financial results for Q2 2025?
What were the Phase 2 results for Xilio's vilastobart in colorectal cancer patients?
How long will Xilio's (XLO) current cash runway last?
What are Xilio's upcoming pipeline milestones for 2025-2026?
What strategic partnerships does Xilio Therapeutics have?
